Evidence map›Paper›PMID 41611998›Full record

Trial reportNature cancer2026

Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial.

Kari L Kendra, Shay L Bellasea, Zeynep Eroglu, Siwen Hu-Lieskovan, Katie M Campbell, William E Carson, David A Wada, Jose A Plaza, Gino K In, Alexandra Ikeguchi and 23 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02775851 (A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02775851 phase2active not recruitingnot on this map

A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2017 to 2027Enrolled57ConditionsDesmoplastic MelanomaArmsBiopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Pembrolizumab
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Kari L KendraOhio State University Wexner Medical Center, Columbus, OH, USA. kari.kendra@osumc.edu.ORCID http://orcid.org/0000-0001-5936-6689
Shay L BellaseaSWOG Statistics and Data Management Center, Seattle, WA, USA.
Zeynep ErogluH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Siwen Hu-LieskovanHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Katie M CampbellJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-6491-4432
William E CarsonOhio State University Wexner Medical Center, Columbus, OH, USA.
David A WadaHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Jose A PlazaOhio State University Wexner Medical Center, Columbus, OH, USA.
Gino K InNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Alexandra IkeguchiUniversity of Oklahoma Stephenson Cancer Center, Oklahoma City, OK, USA.ORCID http://orcid.org/0000-0002-4448-9755
John HyngstromHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Andrew S BrohlH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID http://orcid.org/0000-0002-0071-0534
Bartosz ChmielowskiJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-2374-3320
Nikhil I KhushalaniH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Joseph MarkowitzH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Marcus MonroeHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Carlo M ContrerasOhio State University Wexner Medical Center, Columbus, OH, USA.
Tawnya BowlesIntermountain Medical Center, Murray, UT, USA.
Kurt NormanWestern States Cancer Research, Jefferson Healthcare, Seattle, WA, USA.
Egmidio MedinaJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-3284-5329
Cynthia R GonzalezJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
Ignacio Baselga-CarreteroJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
Ivan Perez GarcilazoJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
Agustin Vega-CrespoJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
Jia Ming ChenJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-3992-9143
Nataly Naser Al DeenJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
Sapna P PatelUniversity of Colorado Cancer Center, Aurora, CO, USA.ORCID http://orcid.org/0000-0003-1339-1517
Kenneth F GrossmannHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Vernon K SondakH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Elad SharonCancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
James MoonSWOG Statistics and Data Management Center, Seattle, WA, USA.
Michael C WuSWOG Statistics and Data Management Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-3357-6570
Antoni RibasJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA. aribas@mednet.ucla.edu.ORCID http://orcid.org/0000-0003-3669-8458

Funding

SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
SWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Catherine M. Tangen · 2014 to 2026
$115.2M
Project 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORICEAU, GATIEN P · 2020 to 2024
$12.8M
Next Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4M
NCI NIH HHS P01 CA244118NCI NIH HHS R35 CA197633NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180888
6 · The paper itself

Abstract

The phase 2 SWOG S1512 trial ( NCT02775851 ) was designed to evaluate the response to pembrolizumab (anti-PD-1) in individuals with desmoplastic melanoma. Here we report the results of cohort A of the trial, evaluating the pathological complete response (pCR) rate of neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma. Secondary endpoints included clinical response rate, overall survival and toxicities. Twenty-eight eligible individuals with resectable desmoplastic melanoma received intravenous pembrolizumab (200 mg) every 3 weeks three times, followed by excision. Tissue samples before treatment, at 3-5 weeks after treatment initiation and at the time of surgery were reviewed. The primary endpoint of pCR rate by local pathological review was 71% (95% confidence interval, 51-87%; P < 0.001), which met the prespecified endpoint. There were two (7%) grade 3 treatment-related adverse events. At three years of follow-up, four participants have died, none known to be from melanoma or adverse events. In conclusion, neoadjuvant pembrolizumab in individuals with resectable desmoplastic melanoma results in a high pCR rate with acceptable safety profile. Clinicaltrials.gov: NCT02775851 .

Indexed as

Antibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsMelanomaNeoadjuvant TherapyProgrammed Cell Death 1 ReceptorSkin NeoplasmsAgedFemaleHumansMaleMiddle AgedPathologic Complete ResponseAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 Receptor

Identifiers

PMID41611998
PMCPMC12948668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.